While new HCV drugs from Gilead Sciences Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) are more expensive in some patient cohorts than regimens based on first-generation protease inhibitors from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Merck & Co. Inc. (NYSE:MRK), the new drugs are on par or cheaper in other populations. However, Gilead's Sovaldi sofosbuvir and J&J's Olysio simeprevir are so much more effective, safer and convenient